Cargando…

Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas

PURPOSE: Radiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparin...

Descripción completa

Detalles Bibliográficos
Autores principales: Baron, Jonathan, Wright, Christopher M., Lee, Daniel Y., Carpenter, Maribel, Manjunath, Shwetha H., Briceño, César A., Chong, Elise, Maity, Amit, Plastaras, John P., Paydar, Ima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288045/
https://www.ncbi.nlm.nih.gov/pubmed/34290991
http://dx.doi.org/10.3389/fonc.2021.716002
_version_ 1783724023410065408
author Baron, Jonathan
Wright, Christopher M.
Lee, Daniel Y.
Carpenter, Maribel
Manjunath, Shwetha H.
Briceño, César A.
Chong, Elise
Maity, Amit
Plastaras, John P.
Paydar, Ima
author_facet Baron, Jonathan
Wright, Christopher M.
Lee, Daniel Y.
Carpenter, Maribel
Manjunath, Shwetha H.
Briceño, César A.
Chong, Elise
Maity, Amit
Plastaras, John P.
Paydar, Ima
author_sort Baron, Jonathan
collection PubMed
description PURPOSE: Radiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparing outcomes following LDRT to moderate-dose RT (MDRT, RT dose 4 – 36 Gy). We present a single institution retrospective analysis comparing outcomes of patients with IOALs following LDRT or MDRT. METHODS: A total of 36 patients treated with 38 consecutive courses of RT were identified; LDRT was delivered for 14 courses and MDRT for 24 courses. Overall response rates (ORR) were recorded according to Deauville or RECIST criteria with a response characterized as a complete response (CR) or partial response. Local control (LC), orbital control (OC), and overall survival (OS) rates were estimated with the Kaplan-Meier method. RT toxicity was graded per CTCAEv5 and compared with the Fisher’s exact test. RESULTS: Median follow-up time was 29 months (m) (range, 4-129m), and median MDRT dose used was 24 Gy (range 21-36 Gy). Overall response rates (ORR) were 100% (CR 50%) and 87.5% (CR 58.3%) following LDRT and MDRT, respectively. OS at 2 years was 100% and 95% for the LDRT and MDRT groups, respectively (p=0.36). LC rates at 2 years was 100% for both LDRT and MDRT groups and at 4 years was 100% and 89% for the LDRT and MDRT groups, respectively (p=0.56). The 4-year OC rate (including both ipsilateral and contralateral relapses) was 80% and 85% for the LDRT and MDRT groups, respectively (p=0.79). No patient required treatment with RT to a previously irradiated orbit. Acute toxicities were reported following 6 LDRT courses compared to 20 MDRT courses (p=.014). No Grade 3 or higher acute toxicities occurred in either group. Late toxicities were reported following 2 LDRT courses compared to 10 MDRT courses (p=0.147). CONCLUSIONS: LDRT produced similar ORR, LC, OC, and OS rates compared to MDRT with fewer acute and minimal late toxicities reported. Future multi-center studies with larger patient numbers are warranted to show significant associations.
format Online
Article
Text
id pubmed-8288045
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82880452021-07-20 Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas Baron, Jonathan Wright, Christopher M. Lee, Daniel Y. Carpenter, Maribel Manjunath, Shwetha H. Briceño, César A. Chong, Elise Maity, Amit Plastaras, John P. Paydar, Ima Front Oncol Oncology PURPOSE: Radiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparing outcomes following LDRT to moderate-dose RT (MDRT, RT dose 4 – 36 Gy). We present a single institution retrospective analysis comparing outcomes of patients with IOALs following LDRT or MDRT. METHODS: A total of 36 patients treated with 38 consecutive courses of RT were identified; LDRT was delivered for 14 courses and MDRT for 24 courses. Overall response rates (ORR) were recorded according to Deauville or RECIST criteria with a response characterized as a complete response (CR) or partial response. Local control (LC), orbital control (OC), and overall survival (OS) rates were estimated with the Kaplan-Meier method. RT toxicity was graded per CTCAEv5 and compared with the Fisher’s exact test. RESULTS: Median follow-up time was 29 months (m) (range, 4-129m), and median MDRT dose used was 24 Gy (range 21-36 Gy). Overall response rates (ORR) were 100% (CR 50%) and 87.5% (CR 58.3%) following LDRT and MDRT, respectively. OS at 2 years was 100% and 95% for the LDRT and MDRT groups, respectively (p=0.36). LC rates at 2 years was 100% for both LDRT and MDRT groups and at 4 years was 100% and 89% for the LDRT and MDRT groups, respectively (p=0.56). The 4-year OC rate (including both ipsilateral and contralateral relapses) was 80% and 85% for the LDRT and MDRT groups, respectively (p=0.79). No patient required treatment with RT to a previously irradiated orbit. Acute toxicities were reported following 6 LDRT courses compared to 20 MDRT courses (p=.014). No Grade 3 or higher acute toxicities occurred in either group. Late toxicities were reported following 2 LDRT courses compared to 10 MDRT courses (p=0.147). CONCLUSIONS: LDRT produced similar ORR, LC, OC, and OS rates compared to MDRT with fewer acute and minimal late toxicities reported. Future multi-center studies with larger patient numbers are warranted to show significant associations. Frontiers Media S.A. 2021-07-05 /pmc/articles/PMC8288045/ /pubmed/34290991 http://dx.doi.org/10.3389/fonc.2021.716002 Text en Copyright © 2021 Baron, Wright, Lee, Carpenter, Manjunath, Briceño, Chong, Maity, Plastaras and Paydar https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Baron, Jonathan
Wright, Christopher M.
Lee, Daniel Y.
Carpenter, Maribel
Manjunath, Shwetha H.
Briceño, César A.
Chong, Elise
Maity, Amit
Plastaras, John P.
Paydar, Ima
Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
title Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
title_full Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
title_fullStr Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
title_full_unstemmed Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
title_short Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
title_sort low-dose radiotherapy versus moderate-dose radiotherapy for the treatment of indolent orbital adnexal lymphomas
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288045/
https://www.ncbi.nlm.nih.gov/pubmed/34290991
http://dx.doi.org/10.3389/fonc.2021.716002
work_keys_str_mv AT baronjonathan lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT wrightchristopherm lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT leedaniely lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT carpentermaribel lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT manjunathshwethah lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT bricenocesara lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT chongelise lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT maityamit lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT plastarasjohnp lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas
AT paydarima lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas